Europe Igg4 Related Disease Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Europe Igg4 Related Disease Market Analysis

  • Healthcare
  • Published Report
  • Oct 2021
  • Europe
  • 350 Pages
  • No of Tables: 185
  • No of Figures: 39

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE IGG4-RELATED DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

5 REGIONAL SUMMARY

5.1 SUMMARY WRITE UP (NORTH AMERICA)

5.1.1 OVERVIEW

5.2 SUMMARY WRITE UP (EUROPE)

5.2.1 OVERVIEW

5.3 SUMMARY WRITE UP (ASIA-PACIFIC)

5.3.1 OVERVIEW

5.4 SUMMARY WRITE UP (SOUTH AMERICA)

5.4.1 OVERVIEW

5.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)

5.5.1 OVERVIEW

6 EPIDEMIOLOGY

7 REGULATORY GUIDELINES FOR EUROPE IGG4-RELATED DISEASE MARKET

7.1 U.S. REGULATORY FRAMEWORK

7.2 EUROPE REGULATORY FRAMEWORK

7.3 JAPAN REGULATORY FRAMEWORK

8 PIPELINE ANALYSIS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISING AWARENESS ABOUT IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)

9.1.2 ESCALATION IN INNOVATION AND TECHNOLOGIES

9.1.3 INCREASE IN RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY

9.2 RESTRAINTS

9.2.1 HIGH COST OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) TREATMENT

9.2.2 ADVERSE EFFECTS ASSOCIATED WITH TREATMENT

9.3 OPPORTUNITIES

9.3.1 RISING EXPENDITURE ON HEALTHCARE

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 GOVERNMENT FUNDING FOR RESEARCH PURPOSE

9.4 CHALLENGE

9.4.1 DIFFICULT DIAGNOSIS AND MANGEMENT OF THE DISEASE

10 IMPACT OF COVID 19 PANDEMIC ON THE MARKET

10.1 PRICE IMPACT

10.2 IMPACT ON SUPPLY CHAIN

10.3 IMPACT ON DEMAND

10.4 STRATEGIC DECISIONS FOR MANUFACTURERS

10.5 CONCLUSION

11 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE

11.1 OVERVIEW

11.2 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS

11.3 RETROPERITONEAL FIBROSIS

11.4 IGG4-RELATED THYROID DISEASE

11.5 IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN)

11.6 IGG4-RELATED SCLEROSING CHOLANGITIS

11.7 TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP)

11.8 IGG4-RELATED PACHYMENINGITIS

11.9 OTHERS

12 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE

12.1 OVERVIEW

12.2 DIAGNOSTIC

12.2.1 IMAGING

12.2.1.1 COMPUTED TOMOGRAPHY (CT)

12.2.1.2 MAGNETIC RESONANCE IMAGING (MRI)

12.2.1.3 PET/CT

12.2.1.4 OTHERS

12.2.2 LABORATORY TESTING (SERUM IGG4 CONCENTRATION)

12.2.3 FLOW CYTOMETRY

12.2.4 OTHERS

12.3 TREATMENT

12.3.1 RITUXIMAB

12.3.2 CYCLOPHOSPHAMIDE

12.3.3 METHOTREXATE

12.3.4 STEROIDS

12.3.4.1 Methylprednisolone

12.3.4.2 Prednisolone

12.3.4.3 others

12.3.5 AZATHIOPRINE

12.3.6 OTHERS

13 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 PARENTERAL

13.3 ORAL

13.4 OTHERS

14 EUROPE IGG4-RELATED DISEASE MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 OTHERS

15 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 HOSPITAL PHARMACY

15.3 RETAIL PHARMACY

15.4 ONLINE PHARMACY

15.5 OTHERS

16 EUROPE IGG4-RELATED DISEASE MARKET, BY REGION

16.1 EUROPE

16.1.1 GERMANY

16.1.2 FRANCE

16.1.3 U.K.

16.1.4 SWITZERLAND

16.1.5 NETHERLANDS

16.1.6 ITALY

16.1.7 SPAIN

16.1.8 AUSTRIA

16.1.9 RUSSIA

16.1.10 HUNGARY

16.1.11 IRELAND

16.1.12 NORWAY

16.1.13 POLAND

16.1.14 TURKEY

16.1.15 BELGIUM

16.1.16 LITHUANIA

16.1.17 REST OF EUROPE

17 EUROPE IGG4-RELATED DISEASE MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 PFIZER INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 AMGEN INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 GENENTECH, INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 COMPANY SHARE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 CELLTRION HEALTHCARE CO., LTD.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACCORD-UK LTD.

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 AMNEAL PHARMACEUTICALS LLC

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 ANI PHARMACEUTICALS, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 ANTARES PHARMA

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BAXTER

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 CIPLA INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 HIKMA PHARMACEUTICALS PLC

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENTS

19.14 INGENUS PHARMACEUTICALS

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 LANNETT

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

19.16 SEBELA PHARMACEUTICALS

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 STI PHARMA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 VIATRIS INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 ZYDUS CADILA

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 COMPANIES WITH PRODUCTS IN PHASE II AND PHASE III CLINICAL TRIALS

20.1 SANOFI

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENT

20.2 XENCOR

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENT

20.3 BRISTOL-MYERS SQUIBB COMPANY

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENTS

20.4 HORIZON THERAPEUTICS PLC

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

TABLE 1 EUROPE IGG4-RELATED DISEASE MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 3 EUROPE IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 4 EUROPE RETROPERITONEAL FIBROSIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 5 EUROPE IGG4-RELATED THYROID DISEASE IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 6 EUROPE IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 7 EUROPE IGG4-RELATED SCLEROSING CHOLANGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 8 EUROPE TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 9 EUROPE IGG4-RELATED PACHYMENINGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 10 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 11 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 12 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 13 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 14 EUROPE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 15 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 16 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 17 EUROPE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 18 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 19 EUROPE PARENTERAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 20 EUROPE ORAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 21 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 22 EUROPE IGG4-RELATED DISEASE MARKET, BY END USERS, 2019-2028 (USD THOUSAND)

TABLE 23 EUROPE HOSPITALS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 24 EUROPE SPECIALTY CLINICS IN EUROPE IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 25 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 26 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 27 EUROPE HOSPITAL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 28 EUROPE RETAIL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 29 EUROPE ONLINE PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 30 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 31 EUROPE IGG4-RELATED DISEASE MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)

TABLE 32 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 33 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 34 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 35 EUROPE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 36 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 37 EUROPE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 38 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 39 EUROPE IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 40 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 41 GERMANY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 42 GERMANY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 43 GERMANY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 44 GERMANY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 45 GERMANY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 46 GERMANY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 47 GERMANY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 48 GERMANY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 49 GERMANY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 50 FRANCE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 51 FRANCE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 52 FRANCE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 53 FRANCE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 54 FRANCE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 55 FRANCE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 56 FRANCE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 57 FRANCE IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 58 FRANCE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 59 U.K. IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 60 U.K. IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 61 U.K. DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 62 U.K. IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 63 U.K. TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 64 U.K. STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 65 U.K. IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 66 U.K. IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 67 U.K. IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 68 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 69 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 70 SWITZERLAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 71 SWITZERLAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 72 SWITZERLAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 73 SWITZERLAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 74 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 75 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 76 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 77 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 78 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 79 NETHERLANDS DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 80 NETHERLANDS IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 81 NETHERLANDS TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 82 NETHERLANDS STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 83 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 84 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 85 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 86 ITALY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 87 ITALY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 88 ITALY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 89 ITALY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 90 ITALY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 91 ITALY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 92 ITALY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 93 ITALY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 94 ITALY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 95 SPAIN IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 96 SPAIN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 97 SPAIN DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 98 SPAIN IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 99 SPAIN TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 100 SPAIN STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 101 SPAIN IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 102 SPAIN IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 103 SPAIN IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 104 AUSTRIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 105 AUSTRIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 106 AUSTRIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 107 AUSTRIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 108 AUSTRIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 109 AUSTRIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 110 AUSTRIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 111 AUSTRIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 112 AUSTRIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 113 RUSSIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 114 RUSSIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 115 RUSSIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 116 RUSSIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 117 RUSSIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 118 RUSSIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 119 RUSSIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 120 RUSSIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 121 RUSSIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 122 HUNGARY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 123 HUNGARY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 124 HUNGARY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 125 HUNGARY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 126 HUNGARY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 127 HUNGARY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 128 HUNGARY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 129 HUNGARY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 130 HUNGARY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 131 IRELAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 132 IRELAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 133 IRELAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 134 IRELAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 135 IRELAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 136 IRELAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 137 IRELAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 138 IRELAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 139 IRELAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 140 NORWAY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 141 NORWAY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 142 NORWAY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 143 NORWAY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 144 NORWAY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 145 NORWAY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 146 NORWAY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 147 NORWAY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 148 NORWAY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 149 POLAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 150 POLAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 151 POLAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 152 POLAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 153 POLAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 154 POLAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 155 POLAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 156 POLAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 157 POLAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 158 TURKEY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 159 TURKEY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 160 TURKEY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 161 TURKEY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 162 TURKEY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 163 TURKEY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 164 TURKEY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 165 TURKEY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 166 TURKEY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 167 BELGIUM IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 168 BELGIUM IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 169 BELGIUM DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 170 BELGIUM IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 171 BELGIUM TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 172 BELGIUM STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 173 BELGIUM IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 174 BELGIUM IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 175 BELGIUM IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 176 LITHUANIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 177 LITHUANIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 178 LITHUANIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 179 LITHUANIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 180 LITHUANIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 181 LITHUANIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 182 LITHUANIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 183 LITHUANIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 184 LITHUANIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 185 REST OF EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

List of Figure

FIGURE 1 EUROPE IGG4-RELATED DISEASE MARKET : SEGMENTATION

FIGURE 2 EUROPE IGG4-RELATED DISEASE MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE IGG4-RELATED DISEASE MARKET : DROC ANALYSIS

FIGURE 4 EUROPE IGG4-RELATED DISEASE MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE IGG4-RELATED DISEASE MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE IGG4-RELATED DISEASE MARKET : INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE IGG4-RELATED DISEASE MARKET : DBMR MARKET POSITION GRID

FIGURE 8 EUROPE IGG4-RELATED DISEASE MARKET : MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE IGG4-RELATED DISEASE MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE IGG4-RELATED DISEASE MARKET : SEGMENTATION

FIGURE 11 INCREASING AWARENESS FOR IGG4-RELATED DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE IGG4-RELATED DISEASE MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE IGG4-RELATED DISEASE MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: EUROPE IGG4-RELATED DISEASE MARKET

FIGURE 14 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2020

FIGURE 15 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

FIGURE 16 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, CAGR (2021-2028)

FIGURE 17 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 18 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, 2020

FIGURE 19 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, 2019-2028 (USD THOUSAND)

FIGURE 20 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 21 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 23 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

FIGURE 24 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 25 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, 2020

FIGURE 27 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, 2019-2028 (USD THOUSAND)

FIGURE 28 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 29 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, LIFELINE CURVE

FIGURE 30 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 31 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

FIGURE 32 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL,CAGR (2021-2028)

FIGURE 33 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 EUROPE IGG4-RELATED DISEASE MARKET: SNAPSHOT (2020)

FIGURE 35 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020)

FIGURE 36 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2021 & 2028)

FIGURE 37 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020 & 2028)

FIGURE 38 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE (2021-2028)

FIGURE 39 EUROPE IGG4-RELATED DISEASEMARKET: COMPANY SHARE 2020 (%)

Frequently Asked Questions

The market is segmented based on Europe IgG4-Related Disease Market, By Disease Type (Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP), Retroperitoneal Fibrosis, IgG4-Related Tubulointerstitial Nephritis (TIN), IgG4-Related Sclerosing Cholangitis IgG4-Related Dacryoadenitis and Sialadenitis, IgG4-Related Pachymeningitis, IgG4-Related Thyroid Disease, Serum IgG4 Concentration, and Others), Type (Diagnostic and Treatment), Route of Administration (Parenteral, Oral and Others), End-User (Hospitals, Specialty Clinics, and Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe). Industry Trends and Forecast to 2028 .
The Europe Igg4 Related Disease Market size was valued at USD 713.58 USD Million in 2020.
The Europe Igg4 Related Disease Market is projected to grow at a CAGR of 3.7% during the forecast period of 2021 to 2028.